Guy's 13 is a mouse monoclonal antibody which specifically recognizes the major cell-surface adhesion protein SA I/II of Streptococcus mutans, one of the major causative agents of dental caries. Passive immunization with Guy's 13 prevents bacterial colonization in humans. To help elucidate the mechanism of prevention of colonization conferred by this antibody, the SA I/II epitope recognized by Guy's 13 was investigated. It was previously established that the epitope is conformational, being assembled from two noncontiguous regions of SA I/II. In the current study, using recombinant fragments of SA I/II and, ultimately, synthetic peptides, the discontinuous epitope was localized to residues 170-218 and 956-969. This work describes the mapping of a novel discontinuous epitope that requires an interaction between each determinant in order for epitope assembly and recognition by antibody to take place. Guy's 13 binds to the assembled epitope but not to these individual epitope fragments. The assembled epitope results from the interaction between the individual antigenic determinants and can be formed by mixing together determinants present on separate polypeptide chains. The data are consistent with one of the epitope fragments adopting a polyproline II-like helical conformation.
INTRODUCTION
The Gram-positive bacterium Streptococcus mutans is one of the main causative agents of dental caries (1) . Adhesion of the bacterium to the tooth surface is mediated by a major bacterial cell surface protein, termed streptococcal antigen I/II (SA I/II) (2) . This protein has been identified in a number of strains and serotypes of S. mutans, and has also been called SR (3) or PAc (4) .
Sequencing of the spaP gene encoding SA I/II (5) and alignment of the predicted amino acid sequence with the antigen I/II sequences from other streptococcal strains and species reveals many common features (6) and on this basis the proteins have been divided into a number of distinct regions (Fig. 1) . These include an alanine-rich repeat (A) region (residues 121-447 of SA I/II from S. mutans NG5) consisting of four tandem repeats of an 82 ammino acid (aa) 1 sequence, a variable (V) region, where most of the sequence variation between antigen I/II homologues occurs and a proline-rich repeat (P) region (aa840-983) consisting of three tandem repeats of a 39aa
sequence, together with a fourth, more degenerate repeat.
The mouse monoclonal antibody Guy's 13, which recognizes SA I/II of S.
mutans and S. sobrinus (7) , has been used successfully to prevent S. mutans colonization and the development of caries in non-human primates (8) and prevents bacterial colonization in human clinical trials (9, 10). Guy's 13 has been expressed, as a secretory immunoglobulin molecule in transgenic Nicotiana tabacum plants (11) , and as a single chain Fv on the surface of the commensal bacterium Lactobacillus zeae (12) , offering possible strategies for passive mucosal immunization against dental caries (13) .
Previous work by our group has established that the epitope recognized by Guy's 13 monoclonal antibody is conformational, being assembled from two regions of SA I/II that are non-contiguous in sequence (14) . Using immunoblotting, it was shown that Guy's 13 recognizes two non-overlapping recombinant polypeptides that show no sequence homology. One part of the discontinuous epitope was shown to reside in a recombinant polypeptide with a recombinant fragment containing the P site. Additionally, we showed that the two binding sites are able to associate with each other, leading to a structure that can subsequently be recognized by Guy's 13. This suggested that the A and P sites, which are widely separated in the linear sequence, are situated in close proximity in the native SA I/II.
The aim of the current work was to map both binding sites in greater detail and, in the process, identify critical residues responsible for forming the discontinuous Guy's 13 epitope. This in turn may give a better understanding of the structure of SA I/II, the nature of the antibody-antigen interaction and provide an insight into how the antibody prevents S. mutans colonization of the oral cavity. 
RESULTS
Mapping of the A-region binding site using competition ELISA. We have previously demonstrated the simultaneous requirement for both the A and P sites in fluid phase assays (14) . In a competition ELISA, Guy's 13 IgG binding to solid phase SA I/II was inhibited using a lysate from E. coli expressing a recombinant fragment of the P-region mixed with lysate from E.
coli expressing an A-region fragment. A-region fragments 114, 115, 116 and 121 ( Fig. 1) were mixed with recombinant P-region fragment Pro0-IV (Fig. 2a) .
When only one fragment was incubated with Guy's 13 (the "PBS" columns),
antibody binding to solid phase SA I/II was unaffected compared to the control wells which received only Guy's 13 (the "no inhibitor" column). Mixing of 114 lysate with Pro0-IV lysate resulted in over 90% inhibition of Guy's 13 IgG binding to solid phase SA I/II (OD 450 < 0.1), consistent with our previous report (14) . When A-region fragments 115 or 121 (which both span the first alaninerich repeat) were mixed with Pro0-IV lysate, >90% inhibition was also observed. In contrast, when A-region fragment 116 (representing the Cterminal half of 114) was mixed with Pro0-IV, inhibition of only 30% was observed.
Recombinant polypeptide 110 (spanning aa984-1539 of SA I/II) which was shown previously to have no Guy's 13-binding activity in immunoblotting or in ELISAs (14) was used as a negative control. The lack of inhibition observed following mixing of the 110 lysate with either Pro0-IV lysate or with each of the A-region lysates (Fig. 2a) confirmed the requirement for the simultaneous presence of both A-and P-region binding sites. Mapping of the binding sites using synthetic peptides. The P-region binding site had previously been mapped to a recombinant polypeptide, representing aa816-983 of SA I/II (14) . To further characterize the binding of Guy's 13 to SA I/II, nineteen overlapping 20-mer peptides spanning the Pregion were synthesized (Table I) . A further peptide, p1037, which lies Cterminal to the P-region was included as a negative control. Each of the coli expressing recombinant fragment Pro0-IV (results not shown).
Homologues of peptide p955. The peptide p955 sequence is located within tandem repeat IV of the proline-rich region of SA I/II. The repeat nature of the P-region suggested that p955-homologous peptides from the other Pregion tandem repeats might also inhibit Guy's 13 binding. Table II shows the sequence of p955 aligned with the three other peptide homologues from Pregion tandem repeats I, II and III which were synthesized and tested for their ability to inhibit Guy's 13 IgG binding to solid phase SA I/II by preincubation with 121 fragment (or with 110 fragment as a negative control).
The results (Fig. 4a) showed that, in addition to p955, peptides p892 and p931 (from P-region repeats II and III, respectively) resulted in 88% inhibition of binding of Guy's 13 to solid-phase SA I/II, whereas p853 (from P-region repeat I) was not an effective inhibitor. The results of competition ELISAs using the N-terminal deleted peptides showed that deletion of the N-terminal residue (Asn) of p955 had no effect on the inhibition of Guy's 13 binding to solid phase SA I/II. Deletion of the first two residues (Asn-Lys), however, reduced by 38% the inhibition exhibited by p955, while deletion of the first three residues completely abolished the inhibitory effect of p955 (data not shown).
The results of the competition ELISAs using the C-terminal deleted peptides showed that deletion of the last five residues of p955 (Thr-Asp-ProVal-Tyr) had very little effect on the ability of the peptide to inhibit Guy's 13 binding to solid phase SA I/II. Deletion of the last six to eight residues resulted in progressively lower levels of inhibition, culminating in total loss of inhibition when the last nine residues were removed (data not shown). The results show that when A-region fragment 121 was adsorbed to the solid phase of an ELISA plate, Pro0-IV lysate or peptide p955 both promoted the binding of Guy's 13 (Fig. 5a) . No effect was seen with a control monoclonal antibody (MOPC 31C) (gray bars). The results using P-region tandem repeat homologues of p955 (see Table II) show that p892 and p931 also promote binding of Guy's 13 to 121, while p853 does not. Lysates 121, 129 and 110 did not promote binding of Guy's 13 to immobilized 121. These findings are consistent with the results of the competition ELISAs ( Fig. 2 and Fig. 4a ) and confirms the simultaneous requirement for both the A-and Pregion binding sites.
The results using the alanine-substituted peptide analogues of p955 in this direct binding ELISA (Fig. 5b ) also mirrored the results obtained using these peptides in the competition ELISAs. Thus, peptides (such as A7, A10 and A13) which are strong promoters of Guy's 13 binding to solid phase 121 fragment are also strong inhibitors (in combination with fragment 121) of Guy's 13 binding to immobilized SA I/II (Fig. 4b) .
As a control, Pro0-IV lysate (encoding the P-region binding site) coated 
DISCUSSION
In an attempt to delineate the Guy's 13 conformational epitope, we made use of earlier findings that the Guy's 13 epitope was formed from noncontiguous sequences that, when added together, were able to reconstitute the Guy's 13 epitope. The epitope is unusual because it can be reassembled in vitro irrespective of whether the two regions lie in cis or in trans. This allowed each binding site to be studied in turn and enabled each to be more finely mapped by cloning and expression of successively smaller recombinant fragments and, ultimately, with synthetic peptides. Although the P site is shown to reside on a peptide, the data from the ASM show that this partial epitope is not defined simply by a linear sequence of residues (22, 23) . Thus many of the residues in this partial epitope are most likely not involved in making direct contact with the complementarity determining region residues of the antibody. Similarly, most of the residues of the A site are also unlikely to be involved in interaction with the paratope. This indicates that each binding site still retains some secondary structure, consisting of independent contact residues interspersed amongst non-contact residues. Non-contact residues may be required for either the formation of a stable secondary structure, or for interactions between the A-and P-region binding sites, which then allows the assembled epitope to be recognized by Guy's 13.
Other workers (24-26) have described the mapping of discontinuous epitopes using synthetic peptides. Those reports have all described antibodies that are able to bind independently to at least two, non-overlapping peptides, indicating that the epitopes are discontinuous and that there is little interaction between the epitope fragments (binding sites) in the assembled epitope. In contrast, Spendlove et al (27) described an antibody which, while able to bind independently to three peptides, showed increased binding when the peptides were mixed together. This synergistic binding is indicative of cooperativity between each of the binding sites within the assembled epitope.
The discontinuous Guy's 13 epitope represents an extreme form of cooperativity. Under the denaturing and reducing conditions of immunoblotting Guy's 13 was shown to interact with SA I/II through two binding sites in an independent fashion (14) . While this is not likely to be representative of the Structural analysis of proline-rich regions in other proteins (28, 29) , where proline is present as every third residue, suggests that these regions adopt a conformation with 3 residues per turn, known as the polyproline II (PP II) helix, with a 3.1 Å rise/residue (30) . By analogy it is predicted that the P-region of SA I/II, which also contains frequently repeating (PXX) n motifs, may also adopt a PP II helix-like conformation (31). The results of this study have demonstrated that A-region sequences of SA I/II are able to interact with P-region sequences. Thus, we hypothesize that the PP II-like helix of the proline-rich region interacts with the alanine-rich region, which itself is predicted to adopt an α-helical structure (5, (33) (34) (35) . The interaction of PP II-like helices with α-helices has been described before for turkey pancreatic polypeptide, a 36-amino acid hormone (28, 36) , where residues 2-8 form a PP II-like helix that is closely packed against an α-helix formed from residues 14-32. Homologous polypeptides from the pancreas of a wide range of species have been isolated and sequenced and, despite sequence variation, secondary structure analyses (37) and immunochemical studies (38) indicate that the tertiary structure involves the interaction of the PP II-and α-helices. This idea is now proposed here as the structural basis for the recognition of SA I/II by Guy's 13. Thus, hydrophobic interactions between the proline side chains of the PP II-helical P-region and side chains from the α-helical A-region permit the assembly of the Guy's 13 epitope.
Thus, although the Guy's 13 epitope is formed from two discontinuous binding sites within SA I/II, each site has a conformational requirement determined by its secondary structure.
Recently, the crystal structure of a recombinant protein spanning the variable (V) region of antigen I/II (SR) from S. mutans serotype f strain OMZ 175 has been determined (39) . While this recombinant protein does not encompass the A-and P-region binding sites defined in our studies, it does include some flanking alanine-rich and proline-rich sequences. The structure shows that the alanine-rich sequences form an α-helix which, indeed, lies in close proximity to the proline-rich sequences. The structure also suggests that the A-and P-regions are orientated in an antiparallel configuration.
Juxtaposition of the A-and P-regions is also suggested by our present report as well as our earlier work. In this regard it is interesting to note that one of the A-region 82aa repeats, with a predicted α-helical structure, has approximately the same length (123 Å) as one of the P-region 39aa repeats, with a proposed (residues 3-15) of p955 is depicted. Gray colored residues had a major effect on p955 function when mutated to alanine. Striped residues only had a moderate effect on p955 function. Unshaded residues are those which, when mutated to Ala, had no effect on p955 function. Amino acid differences between p955 and the other functional peptide homologues (i.e. p892 and p931) are indicated by the arrows. p803  p814  p824  p834  p847  p857  p867  p877  p886  p896  p906  p916  p926  p935  p945  p955  p965  p975  p985  p1037  Pro0-IV  110 -IV  110  p955  A3  A4  A5  A6  A7  A8  A9  A10  A11  A12  A13  A14  A15 
